minimum requirements for reporting fecal microbiota transplant trial

Minimum Requirements for Reporting Fecal Microbiota Transplant Trial

1. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran 2. Division of Digestive Diseases, Rush University Medical Center, Chicago, IL, USA 3. Gastroenterology & Oncology, Henri Mondor Hospital and University Paris-Est CRETEIL (UPEC), Paris, France Shirin Moossavi1, Faraz Bishehsari2, Reza Ansari1, Homayoon Vahedi1, Siavos...

Fecal Microbiota Transplant: Benefits and Risks

We commend the authors of “Weight Gain After Fecal Microbiota Transplantation” for describing this case of obesity after a fecal microbiota transplant (FMT). Fecal microbiota transplant is a highly effective therapy for recurrent Clostridium difficile infection (r-CDI), and the authors discuss possible unintended consequences in a patient after successful FMT, which could be due to alteration o...

Microscopic Colitis After Fecal Microbiota Transplant

Microscopic colitis (MC) is an inflammatory condition of the large bowel that is associated with chronic, nonbloody diarrhea. Colonoscopy usually demonstrates normal mucosa, while tissue biopsy reveals intraepithelial lymphocytes or a subepithelial collagen band. Although no specific antibody has been discovered, MC is associated with several autoimmune disorders such as celiac disease, Hashimo...

Clostridium difficile Infection and Fecal Microbiota Transplant.

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent C...

Factors Affecting Effectiveness of Fecal Microbiota Transplant

Fecal microbiota transplant protocol for clostridium difficile infection.

Fecal microbiota transplant has become more acceptable as a therapeutic for recurrent Clostridium difficile infection. The FDA has an enforcement discretion policy for practitioner's performing this therapy, which includes informed consent for this experimental treatment. This manuscript describes a typical procedure that can be followed that includes the important aspects of this preparation a...